These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 21986212)

  • 1. Neurological complications of acute intermittent porphyria.
    Kuo HC; Huang CC; Chu CC; Lee MJ; Chuang WL; Wu CL; Wu T; Ning HC; Liu CY
    Eur Neurol; 2011; 66(5):247-52. PubMed ID: 21986212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular and biochemical studies of acute intermittent porphyria in 196 patients and their families.
    Kauppinen R; von und zu Fraunberg M
    Clin Chem; 2002 Nov; 48(11):1891-900. PubMed ID: 12406973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute intermittent porphyria in childhood: a population-based study.
    Hultdin J; Schmauch A; Wikberg A; Dahlquist G; Andersson C
    Acta Paediatr; 2003 May; 92(5):562-8. PubMed ID: 12839285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Homozygous hydroxymethylbilane synthase knock-in mice provide pathogenic insights into the severe neurological impairments present in human homozygous dominant acute intermittent porphyria.
    Yasuda M; Gan L; Chen B; Yu C; Zhang J; Gama-Sosa MA; Pollak DD; Berger S; Phillips JD; Edelmann W; Desnick RJ
    Hum Mol Genet; 2019 Jun; 28(11):1755-1767. PubMed ID: 30615115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Porphobilinogen deaminase over-expression in hepatocytes, but not in erythrocytes, prevents accumulation of toxic porphyrin precursors in a mouse model of acute intermittent porphyria.
    Unzu C; Sampedro A; Mauleón I; Vanrell L; Dubrot J; de Salamanca RE; González-Aseguinolaza G; Melero I; Prieto J; Fontanellas A
    J Hepatol; 2010 Mar; 52(3):417-24. PubMed ID: 19815305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Porphobilinogen deaminase deficiency in mice causes a neuropathy resembling that of human hepatic porphyria.
    Lindberg RL; Porcher C; Grandchamp B; Ledermann B; Bürki K; Brandner S; Aguzzi A; Meyer UA
    Nat Genet; 1996 Feb; 12(2):195-9. PubMed ID: 8563760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Porphobilinogen deaminase gene mutations in Polish patients with non-erythroid acute intermittent porphyria.
    Szlendak U; Lipniacka A; Bianketti J; Podolak-Dawidziak M; Bykowska K
    Adv Clin Exp Med; 2015; 24(1):63-8. PubMed ID: 25923088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary excretion of porphyrins, porphobilinogen and δ-aminolaevulinic acid following an attack of acute intermittent porphyria.
    Marsden JT; Rees DC
    J Clin Pathol; 2014 Jan; 67(1):60-5. PubMed ID: 23908454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between biochemical findings, structural and enzymatic abnormalities in mutated HMBS identified in six Israeli families with acute intermittent porphyria.
    Ulbrichova D; Schneider-Yin X; Mamet R; Saudek V; Martasek P; Minder EI; Schoenfeld N
    Blood Cells Mol Dis; 2009; 42(2):167-73. PubMed ID: 19138865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular diagnostics of acute intermittent porphyria.
    Kauppinen R
    Expert Rev Mol Diagn; 2004 Mar; 4(2):243-9. PubMed ID: 14995910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria.
    D'Avola D; López-Franco E; Sangro B; Pañeda A; Grossios N; Gil-Farina I; Benito A; Twisk J; Paz M; Ruiz J; Schmidt M; Petry H; Harper P; de Salamanca RE; Fontanellas A; Prieto J; González-Aseguinolaza G
    J Hepatol; 2016 Oct; 65(4):776-783. PubMed ID: 27212246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal failure affects the enzymatic activities of the three first steps in hepatic heme biosynthesis in the acute intermittent porphyria mouse.
    Unzu C; Sampedro A; Sardh E; Mauleón I; Enríquez de Salamanca R; Prieto J; Salido E; Harper P; Fontanellas A
    PLoS One; 2012; 7(3):e32978. PubMed ID: 22412963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Awareness is the name of the game: clinical and biochemical evaluation of a case of a girl diagnosed with acute intermittent porphyria associated with autism.
    Luder AS; Mamet R; Farbstein I; Schoenfeld N
    Cell Mol Biol (Noisy-le-grand); 2009 Feb; 55(1):19-22. PubMed ID: 19267997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimation and application of biological variation of urinary delta-aminolevulinic acid and porphobilinogen in healthy individuals and in patients with acute intermittent porphyria.
    Aarsand AK; Petersen PH; Sandberg S
    Clin Chem; 2006 Apr; 52(4):650-6. PubMed ID: 16595824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variations in porphobilinogen and 5-aminolevulinic acid concentrations in plasma and urine from asymptomatic carriers of the acute intermittent porphyria gene with increased porphyrin precursor excretion.
    Floderus Y; Sardh E; Möller C; Andersson C; Rejkjaer L; Andersson DE; Harper P
    Clin Chem; 2006 Apr; 52(4):701-7. PubMed ID: 16497943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatocyte transplantation ameliorates the metabolic abnormality in a mouse model of acute intermittent porphyria.
    Yin Z; Wahlin S; Ellis EC; Harper P; Ericzon BG; Nowak G
    Cell Transplant; 2014; 23(9):1153-62. PubMed ID: 23582197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma porphobilinogen as a sensitive biomarker to monitor the clinical and therapeutic course of acute intermittent porphyria attacks.
    Sardh E; Harper P; Andersson DE; Floderus Y
    Eur J Intern Med; 2009 Mar; 20(2):201-7. PubMed ID: 19327613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Acute intermittent porphyria: Long-term follow up of 35 patients].
    Herrero C; Badenas C; Aguilera P; To-Figueras J
    Med Clin (Barc); 2015 Oct; 145(8):332-7. PubMed ID: 25194977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical presentation and electrophysiological findings of porphyric neuropathies: a follow-up study.
    Wu CL; Ro LS; Jung SM; Tsai TC; Chu CC; Lyu RK; Huang CC; Kuo HC
    Muscle Nerve; 2015 Mar; 51(3):363-9. PubMed ID: 24985076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hemodialysis: a therapeutic option for severe attacks of acute intermittent porphyria in developing countries.
    Prabahar MR; Manorajan R; Sathiyakumar D; Soundararajan P; Jayakumar M
    Hemodial Int; 2008 Jan; 12(1):34-8. PubMed ID: 18271838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.